A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM

A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM

Context: The recombinant human erythropoietin (rHuEPO) stimulates the erythropoiesis process. Because this glycoprotein has a short half-life, it needs to be administrated two to three times a week. One of the technics to solve this issue is the PEGgilation. Aims: To evaluate the pharmacokinetics...

Full description

Bibliographic Details
Main Authors:	Gledys Reynaldo, Leyanis Rodríguez, Roberto Menéndez, Joaquín Solazábal, Daniel Amaro, María de los A. Becquer, Yamila Colom, Haydee Gil, Juan C. Polo, Gilberto Castañeda, Braulio Jiménez-Vélez, Jorge Duconge, Eduardo M. Fernández-Sánchez
Format:	Article
Language:	English
Published:	GarVal Editorial Ltda. 2018-05-01
Series:	Journal of Pharmacy & Pharmacognosy Research
Subjects:	erythropoietin non-compartmental analysis PEGylated EPO pharmacodynamics pharmacokinetics reticulocytes
Online Access:	http://jppres.com/jppres/pdf/vol6/jppres17.342_6.3.179.pdf

Similar Items

The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo)
by: Hejaili Fayez
Published: (2009-01-01)

A Conjugated Aptamer-Gold Nanoparticle Fluorescent Probe for Highly Sensitive Detection of rHuEPO-α
by: Zhaoyang Zhang, et al.
Published: (2011-11-01)

Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization
by: A.A. Zuppa, et al.
Published: (2012-08-01)

EQUIVALENCIA TERAPEUTICA ENTRE IOR® EPOCIM Y EPO SIN ALBUMINA EN PACIENTES CON INSUFICIENCIA RENAL CRONICA EN HEMODIÁLISIS Therapeutic equivalence between IOR® EPOCIM and EPO without albumin in patients in hemodyalisis with Chronic renal Insufficiency
by: Jorge F. Pérez-Oliva, et al.
Published: (2008-09-01)

Generation And Characterization Of Rna Aptamer Against rHuEPO-a By Selex Technology
by: Marimuthu, Citartan
Published: (2014)

Equivalencia terapéutica entre IOR® EPOCIM y EPO sin albúmina en pacientes con insuficiencia renal crónica en hemodiálisis
by: Jorge Pérez-Oliva Díaz, et al.
Published: (2008-10-01)

rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients
by: Mehtap Erkmen Uyar, et al.
Published: (2013-01-01)

Recombinant Human Erythropoietin iorEPOCIM® for the treatment of anemia in pediatric cancer patients
by: Liliana Martínez Cárdenas, et al.
Published: (2011-10-01)

RESEARCHES IN TURKEY ON KYRGYZS EPOS
by: Şule GEZER
Published: (2015-04-01)

The Effects of Curcumae Longae Radix, Curcuma phaeocaulis Radix and Their Processed Products on Epo/EpoR Pathway and CD62p
by: Zhimin Chen, et al.
Published: (2018-07-01)

Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration
by: Guan Wang, et al.
Published: (2017-11-01)

Ulisses e o feminino: eros e epos
by: Maria Fernanda Brasete
Published: (2006-01-01)

Erythropoietin Receptor (EpoR) Agonism Is Used to Treat a Wide Range of Disease
by: Fabian Sanchis-Gomar, et al.
Published: (2013-04-01)

“Mythos, logos, epos son la palabra” (Heidegger)
by: Éliane Escoubas
Published: (2009-03-01)

Therapy of an incomplete spinal cord injury by intrathecal injection of EPO and subcutaneous injection of EPO, vitamin C and G-CSF
by: Bader A, et al.
Published: (2017-11-01)

Detection of iron deficiency anaemia by retic haemoglobin (ret-he) in haemodialysis patients on recombinant human erythropoietin (rHuEPO).
by: Ehram, Jamian
Published: (2010)

Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment
by: Farooqahmed S. Kittur, et al.
Published: (2023-04-01)

Efectividad y seguridad del uso de ior® EPOCIM en pacientes en prediálisis Ensayo clínico
by: Alicia Vargas Batista, et al.
Published: (2016-12-01)

Color-Denoting Lexic in the Language of Xinjiang-Oirat and Kalmyk Version of the Epos «Dzhangar»: a Comparative and Statistical Analysis
by: V. Salykova
Published: (2018-06-01)

SOME ASPECTS OF THE HISTORIOGRAPHY OF THE ORIGIN OF THE NART EPOS
by: Inga Tsorieva
Published: (2021-09-01)

On the question of studying Tatar variants of the epos about Idegey
by: Mirgaleev I.M., et al.
Published: (2023-12-01)

«TO EXPOSE OUR TERRIBLE AGE»: THE POETIC EPOS OF ELLA BOBROWA
by: Galina L. Nefagina
Published: (2019-06-01)

Supplementation of evening primrose oil (EPO) - benefits and limitations. Results of the latest studies
by: Sylwia Grosman, et al.
Published: (2023-05-01)

R&D Investments, EPO Patent Applications and the Economic Heterogeneity within the EU
by: Potužáková Zuzana, et al.
Published: (2018-06-01)

The Effects of Exercise in Hypoxia and Normoxia Conditions on Endothelin-1 and EPO in Endurance Runners
by: Roohollah Mohammadi Mirzaei
Published: (2020-07-01)

El conteo automático de reticulocitos: una herramienta de uso diagnóstico, clínico e investigativo
by: Laser H Hernández Reyes, et al.

Dynamic and Static Attributes of Spae and Time in Kalmyk Heroic Epos «Dzhangar»
by: Tsagan Seleeeva
Published: (2018-06-01)

Local YB-1, Epo, and EpoR concentrations in fractured bones: results from a porcine model of multiple trauma
by: Felix Marius Bläsius, et al.
Published: (2023-01-01)

EPO rs1617640 A>C is a Protective Factor for Chronic Obstructive Pulmonary Disease: A Case Control Study
by: Yunchao Wang, et al.
Published: (2023-09-01)

Ranges for Reticulocyte Fractions and Reticulocyte Hemoglobin of Mongolian Donors
by: Purevjal Otgonbayar, et al.
Published: (2017-02-01)

Probleme des Studiums des Kalmückischen heldenhaften epos «Dzhangar» am Anfang des 21. Jahrhunderts
by: T. G. Basangova
Published: (2021-12-01)

Time Delay and Epo Dose Modulation in a Multilevel Model for Erythropoiesis
by: Xin Lai, et al.
Published: (2009-03-01)

IDENTIFICATION OF EPO-Fс FUSION PROTEIN BY MEANS OF POLYACRYLAMIDE GEL-ELECTROPHORESIS WITH ISOELECTROFOCUSING (IEF-PAGE)AND IN PRESENCE OF SODIUM DODECYLSULPHATE (SDS-PAGE)/ LAUROYLSARCOSINATE (SAR-PAGE) FOR THE PURPOSE OF ANTI-DOPING CONTROL
by: P. V. Postnikov, et al.
Published: (2016-10-01)

miR-122 regulates the JAK-STAT signalling pathway by down-regulating EPO in the mammary gland during Streptococcus agalactiae-induced mastitis
by: Junhua Pu, et al.
Published: (2020-12-01)

Pharmaceutical Care for pediatric and adult patients in acute or chronic rhinosinusitis according to the EPOS 2020 guidelines
by: Magdalena Beata Skarzynska, et al.
Published: (2021-01-01)

Expression and Variations in <i>EPO</i> Associated with Oxygen Metabolism in Tibetan Sheep
by: Yue Ren, et al.
Published: (2024-02-01)

Insights into the invasion biology of Plasmodium vivax
by: Surendra Kumar Prajapati, et al.
Published: (2013-03-01)

The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor
by: Debbra Y. Knorr, et al.
Published: (2023-04-01)

Effects of EPO Gene on Growth and Apoptosis of Lung Adenocarcinoma Cell Line A549
by: Jianqing WU, et al.
Published: (2009-09-01)

Epos of the Mongolic Peoples: Publications within the Bilingual Academic Book Series ‘Epos of the USSR’s Peoples’
by: A. Alieva
Published: (2018-12-01)